Angels, Juan Roig’s funding firm belonging to Marina de Empresas, has invested in Biozell, the Valencian three way partnership car in biotechnology, pharmaceutical and well being firms promoted by Ángela Pérez, vp of Health in Code and Rei Jaume I 2022 Award for Entrepreneur .
Biozell is led by Ángela Pérez and Fernando Ibáñez, General Director of Ethics and CEO of Biohub VLC, the enterprise group for progress and innovation in well being and human well-being situated within the Marina de València, of which Biozell is the funding arm in firms within the sector.
“Biozell has the twin objective of supporting the expansion of modern and impactful tasks in well being and biotechnology, and in addition giving non-public buyers (enterprise angels) entry to such a posh however essential sector, hand in hand with skilled individuals”, he declares. Ángela Pérez in a press release.
“Angels invests in numbers one and Ángela Pérez is an entrepreneur and a nationwide benchmark within the discipline of entrepreneurship and science; therefore our funding in Biozell, an initiative that she leads. We are certain that the fund will promote well being firms and cutting-edge biotechnology that can provide revolutionary options”, affirms the overall director of Angels, Pepe Peris.
Diagnosis and therapy most cancers
The first funding of the car after the entry of Angels has been made in Ysotope Theranostics, a startup that’s being promoted by Lanzadera, an accelerator that’s a part of Marina de Empresas.
Ysotope is a Deep Tech startup centered on the event, validation and exploitation of radiopharmaceuticals for precision oncology. The firm combines medicine with radioactive isotopes, growing the accuracy and effectiveness of prognosis and therapy for most cancers sufferers.
The firm is led by Carlos Langeber and Natalia Benito, specialists within the improvement of deep tech startups, along with Dr. Raúl Herance, head of Chemistry-Radiochemistry and Preclinical Molecular Imaging on the Vall d’Hebron Research Institute.
“Having the help and funding of Biozell is a privilege that can make it simpler for us to validate our know-how and can permit us to proceed progressing within the improvement of options for a extra customized drugs”, emphasizes Carlos Langeber, CEO of the corporate.
Topics